Back to Search
Start Over
Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
- Source :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 36(2)
- Publication Year :
- 2021
-
Abstract
- Ponesimod is a sphingosine 1-phosphate (S1P) receptor (S1PR) modulator that was recently approved for treating relapsing forms of multiple sclerosis (MS). Three other FDA-approved S1PR modulators for MS-fingolimod, siponimod, and ozanimod-share peripheral immunological effects via common S1P
Details
- ISSN :
- 15306860
- Volume :
- 36
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- Accession number :
- edsair.pmid..........c3e779b4b977d01f9a2bae4228b30dd4